Surface Modification and Functionalization of Sorafenib-Loaded PLGA Nanoparticles for Targeting Hepatocellular and Renal Cell Carcinoma
The aim of this study is to improve the therapeutic effectiveness of the sorafenib loaded polymeric nanoparticles, surface modified by the pluronic F-127 for the treatment of hepatocellular (HCC) and renal cell carcinomas (RCC). Poly Lactic co-glycolic acid (PLGA) was used to encapsulate sorafenib by simple modified solvent evaporation technique. The nanoparticles were prepared with different concentration of sorafenib and pluronic F-127 keeping PLGA concentration constant. There were no incompatibilities among the sorafenib, PLGA and pluronic F-127 showing that the integrity of polymer, stabilizer and drug remain the same under different conditions. The size of the coated and plain PLGA nanoparticles were ~140 ± 14.7 nm and ~ 200 ± 10.1 nm, respectively. The in-vitro release studies demonstrated that the PLGA controlled the release of sorafenib, avoiding the initial burst release. The effect of coated and plain nanoformulations was found out in squamous cell carcinoma cells. The results showed that surface modified nanoparticles treated hepatocellular and renal carcinoma in a better way as compared to plain PLGA nanoparticles and free dug by keeping the dose constant (20 mg/kg body weight).The targeted delivery of polymeric PLGA nanoparticles into squamous cell carcinoma was improved. The pharmacokinetic parameters have been improved significantly as compared to the reported nanoformulations..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Preprints.org - (2023) vom: 19. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khan, Ismail [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.20944/preprints202308.1277.v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
preprintsorg040556069 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | preprintsorg040556069 | ||
| 003 | DE-627 | ||
| 005 | 20231224120228.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230819s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.20944/preprints202308.1277.v1 |2 doi | |
| 024 | 7 | |a 10.20944/preprints202308.1277.v1 |2 doi | |
| 035 | |a (DE-627)preprintsorg040556069 | ||
| 035 | |a (preprintsorg)10.20944/preprints202308.1277 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khan, Ismail |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Surface Modification and Functionalization of Sorafenib-Loaded PLGA Nanoparticles for Targeting Hepatocellular and Renal Cell Carcinoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The aim of this study is to improve the therapeutic effectiveness of the sorafenib loaded polymeric nanoparticles, surface modified by the pluronic F-127 for the treatment of hepatocellular (HCC) and renal cell carcinomas (RCC). Poly Lactic co-glycolic acid (PLGA) was used to encapsulate sorafenib by simple modified solvent evaporation technique. The nanoparticles were prepared with different concentration of sorafenib and pluronic F-127 keeping PLGA concentration constant. There were no incompatibilities among the sorafenib, PLGA and pluronic F-127 showing that the integrity of polymer, stabilizer and drug remain the same under different conditions. The size of the coated and plain PLGA nanoparticles were ~140 ± 14.7 nm and ~ 200 ± 10.1 nm, respectively. The in-vitro release studies demonstrated that the PLGA controlled the release of sorafenib, avoiding the initial burst release. The effect of coated and plain nanoformulations was found out in squamous cell carcinoma cells. The results showed that surface modified nanoparticles treated hepatocellular and renal carcinoma in a better way as compared to plain PLGA nanoparticles and free dug by keeping the dose constant (20 mg/kg body weight).The targeted delivery of polymeric PLGA nanoparticles into squamous cell carcinoma was improved. The pharmacokinetic parameters have been improved significantly as compared to the reported nanoformulations. | ||
| 700 | 1 | |a Iqbal, Zafar |4 aut | |
| 700 | 1 | |a Khan, Abad |0 (orcid)0000-0003-0928-8242 |4 aut | |
| 700 | 1 | |a Ahmad, Lateef |4 aut | |
| 700 | 1 | |a Khan, Amjad |4 aut | |
| 700 | 1 | |a Khan, Saeed Ahmad |0 (orcid)0000-0001-5606-2719 |4 aut | |
| 700 | 1 | |a Kazi, Mohsin |0 (orcid)0000-0002-5611-0378 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Preprints.org |g (2023) vom: 19. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:19 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.20944/preprints202308.1277.v1 |z kostenfrei |3 Volltext |
| 912 | |a preprintsorg | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 19 |c 12 | ||